Plain-English translation of NCT06726291 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing Akynzeo (a combination of two anti-nausea drugs) to help women with endometrial cancer who are receiving chemotherapy. Nausea and vomiting are among the most feared side effects of cancer treatment, and women are at particularly high risk for these problems. The study will also explore how this medication affects quality of life and daily activities.
Nausea and vomiting from chemotherapy can be so severe that patients may delay or skip doses, or need lower doses of their cancer medicine. Women with gynecological cancers like endometrial cancer face even higher risk because of where the cancer can spread. This trial aims to see if this medication can better protect patients from these debilitating side effects.
You likely qualify if…
You likely don't qualify if…
You will receive the nausea-prevention medication as part of your standard chemotherapy treatment for endometrial cancer. You will also complete surveys and questionnaires about how you feel, how nausea affects your daily life, and your expectations about side effects. The study will track your experience across multiple chemotherapy cycles and ask you to report your symptoms to your healthcare team.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Italy